Maximus Inc designs, develops, and delivers programs enabling people to access vital government services... Show more
Maximus, Inc. is a leading provider of tech-enabled business process services (BPS), which means it runs large, complex administrative and clinical programs on behalf of government agencies. The company operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S., with U.S. Federal Services contributing the majority of revenue. Its customer base includes agencies such as the Centers for Medicare & Medicaid Services (CMS), the VA, the Internal Revenue Service (IRS), and the Transportation Security Administration (TSA).
Maximus's structural advantages include deep institutional knowledge of entitlement programs, a highly variable cost model, and long-tenured client relationships with contracts averaging well over seven years. A recompete win rate near 90% underscores the difficulty competitors face in displacing an incumbent that already operates mission-critical infrastructure at scale. The company's emphasis on artificial intelligence (AI) and automation—positioned internally as an early mover in applying these tools to government workflows—could support margin expansion and reinforce its competitive moat over the medium term.
The key structural risk is concentration: a small number of large contracts account for a substantial portion of revenue, so the loss or repricing of any major award can materially shift the outlook.
Several developments could meaningfully shape investor sentiment in the coming quarters. First, the fiscal 2026 fourth-quarter earnings release will provide a reset on whether the temporary suspension of performance incentives tied to the VA medical disability exam program has fully run its course, and whether management reaffirms or adjusts guidance for fiscal 2027.
Second, implementation of the Medicaid provisions of recent federal legislation is a significant medium-term driver. Beginning in January 2027, many states must conduct more frequent eligibility determinations and introduce work requirements for expansion populations. Because Maximus already provides eligibility support to numerous expansion states, this policy shift could translate into higher per-beneficiary activity levels and expanded scope on existing contracts.
Third, the company's sales pipeline—reported in the tens of billions of dollars—remains weighted toward new work, suggesting that award activity in 2027 and beyond could fuel organic growth even if near-term book-to-bill (the ratio of new awards to revenue) has been depressed by delayed federal procurement decisions.
On the analyst front, coverage remains thin but constructive. Consensus data from S&P Global-polled analysts reflects a "Buy" rating with an average 12-month price target in the low-to-mid $90s and a range spanning roughly $75 to $110. BTIG reaffirmed a Buy rating with a $100 price target in July 2026. While target revisions have been mixed as guidance evolved, the prevailing consensus stance suggests analysts remain net-positive on the company's longer-term positioning.
Maximus's trajectory is closely tied to federal and state government budgets, which are influenced by political priorities rather than consumer demand cycles. Entitlement and health services programs benefit from relatively stable, mandatory funding, providing a degree of insulation from discretionary spending cuts. However, government shutdowns, continuing resolutions, and slower award decisions can delay new contract starts and payment collections.
Interest rates matter indirectly: higher borrowing costs can affect the company's cost of capital and debt service, while also influencing the valuation multiple investors apply to a mid-single-digit grower. Labor inflation is a direct cost input, though Maximus's variable cost structure and growing use of automation help mitigate margin pressure. Finally, the broader push toward digital government services and AI-enabled citizen experiences aligns favorably with the company's technology investments, positioning it to capture modernization-related spending.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. It is intended to help users identify developing trends, evaluate potential breakouts or reversals, and compare predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support more timely decision-making. For investors monitoring Maximus and similar names, the platform offers a data-driven complement to fundamental analysis.
Looking toward 2026 and beyond, Maximus's story centers on a handful of structural themes. AI and automation adoption offers a path to improved operating margins and differentiated bids in a competitive government-services market. Policy expansion—particularly the 2027 Medicaid redetermination and work-requirement mandates—could broaden the addressable market in the U.S. Services segment. Meanwhile, the VA medical disability exam program remains a bellwether for the Federal Services segment's profitability.
Capital allocation is another recurring theme: the company has repurchased a meaningful portion of its shares and raised its dividend, signaling management's confidence in free cash flow generation. Its stated priority remains internal organic investment ahead of buybacks and mergers and acquisitions (M&A), a disciplined approach that could support earnings per share growth even if revenue growth remains in the low single digits.
Consensus expectations suggest modest but positive growth, with analysts forecasting mid-single-digit earnings and revenue expansion. Key watch items include the pace of federal award activity, resolution of outstanding litigation, and whether new Medicaid work requirements generate the volume uplift management anticipates. These factors, rather than day-to-day price moves, are likely to determine the company's long-term investment narrative.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GOVZ | 32.71 | 0.04 | +0.12% |
| iShares 25+ Year Treasury STRIPS Bond ETF (GOVZ) | |||
| NVDG | 18.84 | N/A | N/A |
| Leverage Shares 2X Long Nvda Daily ETF | |||
| FXB | 125.98 | -0.44 | -0.35% |
| Invesco CurrencyShares British Pound Sterling Trust (FXB) | |||
| IMCB | 93.54 | -1.68 | -1.76% |
| iShares Morningstar Mid-Cap ETF (IMCB) | |||
| STHH | 9.36 | -0.19 | -2.03% |
| STMICROELECTRONICS NV ADRHEDGED | |||
A.I.dvisor indicates that over the last year, MMS has been loosely correlated with ICFI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MMS jumps, then ICFI could also see price increases.
| Ticker / NAME | Correlation To MMS | 1D Price Change % | ||
|---|---|---|---|---|
| MMS | 100% | -5.00% | ||
| ICFI - MMS | 44% Loosely correlated | -1.94% | ||
| TRI - MMS | 44% Loosely correlated | -3.23% | ||
| BRC - MMS | 42% Loosely correlated | -1.98% | ||
| RELX - MMS | 40% Loosely correlated | -0.49% | ||
| BAH - MMS | 39% Loosely correlated | -1.67% | ||
More | ||||
| Ticker / NAME | Correlation To MMS | 1D Price Change % |
|---|---|---|
| MMS | 100% | -5.00% |
| Office Equipment/Supplies industry (45 stocks) | -2% Poorly correlated | +196.02% |
| Producer Manufacturing industry (346 stocks) | -4% Poorly correlated | +20.74% |
a provider of business process services to government health and human services agencies
Industry OfficeEquipmentSupplies
MMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 39 cases where MMS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 72%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for MMS crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +1.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMS advanced for three days, in 157 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Aroon Indicator entered an Uptrend today. In 99 of 186 cases where MMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 53%.
The 10-day RSI Indicator for MMS moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 15 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMS as a result. In 54 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for MMS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 21 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.970) is normal, around the industry mean (5.887). P/E Ratio (9.604) is within average values for comparable stocks, (33.618). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (1.946). Dividend Yield (0.020) settles around the average of (0.025) among similar stocks. P/S Ratio (0.604) is also within normal values, averaging (9.907).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. MMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.